Mortality and biochemical recurrence after surgery, brachytherapy, or external radiotherapy for localized prostate cancer: a 10-year follow-up cohort study
- PMID: 35869124
- PMCID: PMC9307750
- DOI: 10.1038/s41598-022-16395-w
Mortality and biochemical recurrence after surgery, brachytherapy, or external radiotherapy for localized prostate cancer: a 10-year follow-up cohort study
Abstract
To compare the effectiveness at ten years of follow-up of radical prostatectomy, brachytherapy and external radiotherapy, in terms of overall survival, prostate cancer-specific mortality and biochemical recurrence. Cohort of men diagnosed with localized prostate cancer (T1/T2 and low/intermediate risk) from ten Spanish hospitals, followed for 10 years. The treatment selection was decided jointly by patients and physicians. Of 704 participants, 192 were treated with open radical retropubic prostatectomy, 317 with 125I brachytherapy alone, and 195 with 3D external beam radiation. We evaluated overall survival, prostate cancer-specific mortality, and biochemical recurrence. Kaplan-Meier estimators were plotted, and Cox proportional-hazards regression models were constructed to estimate hazard ratios (HR), adjusted by propensity scores. Of the 704 participants, 542 patients were alive ten years after treatment, and a total of 13 patients have been lost during follow-up. After adjusting by propensity score and Gleason score, brachytherapy and external radiotherapy were not associated with decreased 10-year overall survival (aHR = 1.36, p = 0.292 and aHR = 1.44, p = 0.222), but presented higher biochemical recurrence (aHR = 1.93, p = 0.004 and aHR = 2.56, p < 0.001) than radical prostatectomy at ten years of follow-up. Higher prostate cancer-specific mortality was also observed in external radiotherapy (aHR = 9.37, p = 0.015). Novel long-term results are provided on the effectiveness of brachytherapy to control localized prostate cancer ten years after treatment, compared to radical prostatectomy and external radiotherapy, presenting high overall survival, similarly to radical prostatectomy, but higher risk of biochemical progression. These findings provide valuable information to facilitate shared clinical decision-making.Study identifier at ClinicalTrials.gov: NCT01492751.
© 2022. The Author(s).
Conflict of interest statement
The authors declare no competing interests.
Figures

Similar articles
-
A systematic overview of radiation therapy effects in prostate cancer.Acta Oncol. 2004;43(4):316-81. doi: 10.1080/02841860410030661. Acta Oncol. 2004. PMID: 15303499
-
Surgery Versus Radiotherapy for Clinically-localized Prostate Cancer: A Systematic Review and Meta-analysis.Eur Urol. 2016 Jul;70(1):21-30. doi: 10.1016/j.eururo.2015.11.010. Epub 2015 Dec 15. Eur Urol. 2016. PMID: 26700655
-
Systematic review: comparative effectiveness and harms of treatments for clinically localized prostate cancer.Ann Intern Med. 2008 Mar 18;148(6):435-48. doi: 10.7326/0003-4819-148-6-200803180-00209. Epub 2008 Feb 4. Ann Intern Med. 2008. PMID: 18252677
-
Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer.Cochrane Database Syst Rev. 2006 Oct 18;2006(4):CD006019. doi: 10.1002/14651858.CD006019.pub2. Cochrane Database Syst Rev. 2006. PMID: 17054269 Free PMC article.
-
Low-dose rate brachytherapy for men with localized prostate cancer.Cochrane Database Syst Rev. 2011 Jul 6;(7):CD008871. doi: 10.1002/14651858.CD008871.pub2. Cochrane Database Syst Rev. 2011. PMID: 21735436
Cited by
-
68Ga-PSMA PET/CT in early relapsed prostate cancer patients after radical therapy.Sci Rep. 2022 Nov 28;12(1):20500. doi: 10.1038/s41598-022-24688-3. Sci Rep. 2022. PMID: 36443430 Free PMC article.
-
Clinical and functional outcomes for risk-appropriate treatments for prostate cancer.BJUI Compass. 2023 Sep 12;5(1):109-120. doi: 10.1002/bco2.288. eCollection 2024 Jan. BJUI Compass. 2023. PMID: 38179028 Free PMC article.
-
Immunological facets of prostate cancer and the potential of immune checkpoint inhibition in disease management.Theranostics. 2024 Oct 21;14(18):6913-6934. doi: 10.7150/thno.100555. eCollection 2024. Theranostics. 2024. PMID: 39629128 Free PMC article. Review.
-
Comparison of mpMRI and 68Ga-PSMA-PET/CT in the Assessment of the Primary Tumors in Predominant Low-/Intermediate-Risk Prostate Cancer.Diagnostics (Basel). 2025 May 28;15(11):1358. doi: 10.3390/diagnostics15111358. Diagnostics (Basel). 2025. PMID: 40506931 Free PMC article.
-
Comparison of the Oncological and Functional Outcomes of Brachytherapy and Radical Prostatectomy for Localized Prostate Cancer.Medicina (Kaunas). 2022 Oct 2;58(10):1387. doi: 10.3390/medicina58101387. Medicina (Kaunas). 2022. PMID: 36295548 Free PMC article.